NCT06731842 (ROADAD) is a NA clinical trial of 18F-RO948 in Alzheimer´s Disease, sponsored by Karolinska Institutet.

Who is sponsoring NCT06731842?

NCT06731842 is sponsored by Karolinska Institutet.

What drugs are being tested in NCT06731842?

Interventions in NCT06731842: 18F-RO948.

What condition does NCT06731842 study?

NCT06731842 studies Alzheimer´s Disease.

Is NCT06731842 still recruiting?

NCT06731842 is currently enrolling by invitation. Last updated 12 December 2024.

Last reviewed 2024-12-12 · How we verify

NCT06731842: ROADAD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Molecular PET Imaging and Plasma Biomarkers in Alzheimer´s Disease and Other Neurodegenerative Diseases

ENROLLING BY INVITATION NA Last updated 12 December 2024

What this trial tests

NA trial testing 18F-RO948 in Alzheimer´s Disease in 100 participants. Enrolling by invitation.

Timeline

15 May 2022

Primary endpoint
31 December 2027

31 December 2027

Quick facts

Lead sponsor	Karolinska Institutet
Phase	NA
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	100
Start date	15 May 2022
Primary completion	31 December 2027
Estimated completion	31 December 2027
Sites	1 location across Sweden

Drugs / interventions tested

18F-RO948

Conditions studied

Alzheimer´s Disease — all drugs for Alzheimer´s Disease →

Sponsor

Karolinska Institutet

Who can join

Adults 30 to 85, any sex, with Alzheimer´s Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multi-modal PET tracer study with the aim of studying the time course of regional deposition of tau in brain of subjects with high risk of being carriers of autosomal dominant Alzheimer´s disease and sporadic early onset and late onset Alzheimer´s disease patient (EOAD, LOAD) in tertiary memory clinic cohort in relation to MRI brain changes, plasma biomarker levels and cognitive performance.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials.
Harris GA, Hirschfeld LR, Gonzalez MI, Pritchard MC, et al · · 2025 · cited 8× · PMID 40462159 · DOI 10.1186/s13195-025-01775-x

Verify or expand the search:

Other Karolinska Institutet trials

Trials by the same sponsor.

NCT06359262 — Evaluating the Hope@School Prevention Program · NA · not yet recruiting
NCT07289490 — Bilateral vs Unilateral Inguinal Hernia Repairs With an Asymptomatic Inguinal Hernia in Bilateral Hernias · NA · not yet recruiting
NCT06894264 — Emotion Processing and Regulation in People With Intellectual Disability · NA · not yet recruiting
NCT07494266 — Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited · NA · not yet recruiting
NCT07442032 — Cardiovascular Phenotypes in Sepsis · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06731842 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karolinska Institutet
Last refreshed: 12 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06731842.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing